Optimalizace kombinovaných režimů CVD (Cyklofosfamid, Velcade, Dexametazon) v České Republice: pilotní analýza režimů CVD junior a CVD senior s nižším dávkováním u nemocných s relabujícím mnohočetným myelomem.
| Title in English | Optimization of CVD (Cyclophosphamide, Velcade, Dexamethason) combined regimens in the Czech Republic: A Pilot analysis of CVD junior and CVD senior regimens with lower dosage in patients with relapsing multiple myeloma |
|---|---|
| Authors | |
| Year of publication | 2008 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | The new drugs became a part of standard treatment in multiple myeloma (MM), which lead in a chance for longer survival for the patients. Further optimization, focused on the favourable efficacy/toxicity ratio, is essential. In this trial, we have evaluated the potential of combinative regimen CVD (Cyclophosphamide, Bortezomib (Velcade), Dexamethasone) reduced intensity (CVD senior; 50% reduction) in elderly pts and/or pts with poor status performance with relapsed MM. The results were compared with CVD junior regimen outcome used at the same time in pts aged < 65 years and good status performance. The one center analysis we present will be enlarged for more centres in Czech Republic. The reduced CVD senior regimen is tolerated better than CVD junior, but overall response is not as good as in CVD junior group (ORR 36,4% vs 76,9%). The results could be influenced by the higher pretreatment and worse prognostic parameters (ISS 3 - 50% vs 9%) in CVD senior group. The analysis from all centers will clarify these datas. |